SCHEMBL2498502

SCHEMBL2498502

CCOC(=O)CC(=O)N(C)c1c(C(=O)OC)sc(Br)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
TSHR P16473 5/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 4/20 0.40
HPGD P15428 3/20 0.40
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
DUSP3 P51452 1/20 0.38
PTPN5 P54829 1/20 0.38
PTPN11 Q06124 1/20 0.38
GAA P10253 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664659 0.82 ALDH1A1 (0.41) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL2497494 0.77 ALDH1A1 (0.37) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL3907696 0.73 ALDH1A1 (0.43) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL2493883 0.70 KMT2A (0.51) ALDH1A1HTTMAPTMEN1KMT2A
SCHEMBL14485231 0.69 ALDH1A1 (0.47) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL3911917 0.68 PTPN1 (0.49) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL3907317 0.67 MAPT (0.44) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL23553009 0.66 CA12 (0.44) ALDH1A1TSHRHTTMEN1KMT2A
SCHEMBL168011 0.66 FHIT (0.56) ALDH1A1TSHRHTTMAPTMEN1
SCHEMBL2497681 0.66 ALDH1A1 (0.46) ALDH1A1TSHRHTTMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150251-B9 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2013-02-27 EP disclosed
EP-2150251-B1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2012-06-27 EP disclosed
US-8030346-B2 Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2011-10-04 US disclosed
EP-2150251-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-10 EP disclosed
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008137060-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity EGLN3, HIF1AN, EGLN2 ALDH1A1 108/4885TSHR 3671/4885HTT 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.